RxSight, Inc. (NASDAQ:RXST) Shares Bought by Doheny Asset Management CA

Doheny Asset Management CA increased its position in RxSight, Inc. (NASDAQ:RXST) by 51.7% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,490 shares of the company’s stock after acquiring an additional 4,940 shares during the period. Doheny Asset Management CA’s holdings in RxSight were worth $872,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the company. RA Capital Management L.P. grew its holdings in shares of RxSight by 1.1% in the 1st quarter. RA Capital Management L.P. now owns 3,442,825 shares of the company’s stock worth $177,581,000 after acquiring an additional 38,540 shares during the period. Vanguard Group Inc. grew its holdings in shares of RxSight by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 1,524,510 shares of the company’s stock worth $78,634,000 after acquiring an additional 40,500 shares during the period. Driehaus Capital Management LLC grew its holdings in shares of RxSight by 74.9% in the 2nd quarter. Driehaus Capital Management LLC now owns 706,162 shares of the company’s stock worth $42,490,000 after acquiring an additional 302,367 shares during the period. Parkman Healthcare Partners LLC grew its holdings in shares of RxSight by 34.5% in the 4th quarter. Parkman Healthcare Partners LLC now owns 513,032 shares of the company’s stock worth $20,685,000 after acquiring an additional 131,701 shares during the period. Finally, Baillie Gifford & Co. grew its holdings in shares of RxSight by 438.8% in the 2nd quarter. Baillie Gifford & Co. now owns 358,215 shares of the company’s stock worth $21,554,000 after acquiring an additional 291,733 shares during the period. Institutional investors and hedge funds own 78.78% of the company’s stock.

Insider Buying and Selling

In related news, insider Ilya Goldshleger sold 9,000 shares of the stock in a transaction on Monday, August 5th. The stock was sold at an average price of $39.25, for a total value of $353,250.00. Following the transaction, the insider now directly owns 42,246 shares of the company’s stock, valued at approximately $1,658,155.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, insider Ilya Goldshleger sold 9,000 shares of the stock in a transaction on Monday, August 5th. The stock was sold at an average price of $39.25, for a total value of $353,250.00. Following the transaction, the insider now directly owns 42,246 shares of the company’s stock, valued at approximately $1,658,155.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Shelley B. Thunen sold 10,000 shares of the stock in a transaction on Monday, July 1st. The shares were sold at an average price of $58.61, for a total value of $586,100.00. Following the completion of the sale, the chief financial officer now owns 13,938 shares of the company’s stock, valued at $816,906.18. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 25,200 shares of company stock valued at $1,267,516. 9.36% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on RXST shares. Wells Fargo & Company lowered their price target on RxSight from $68.00 to $54.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. Needham & Company LLC reaffirmed a “buy” rating and issued a $66.00 target price on shares of RxSight in a research note on Friday, September 13th. Stifel Nicolaus reduced their target price on RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. BTIG Research upped their target price on RxSight from $72.00 to $73.00 and gave the company a “buy” rating in a research note on Monday, July 15th. Finally, Oppenheimer reduced their target price on RxSight from $72.00 to $65.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 6th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $60.14.

RxSight Stock Down 0.7 %

Shares of RxSight stock opened at $48.54 on Friday. RxSight, Inc. has a fifty-two week low of $20.66 and a fifty-two week high of $66.54. The firm has a market cap of $1.80 billion, a PE ratio of -38.52 and a beta of 1.22. The business’s fifty day moving average is $51.15 and its two-hundred day moving average is $53.84.

RxSight (NASDAQ:RXST) last issued its earnings results on Monday, August 5th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.06. The business had revenue of $34.89 million for the quarter, compared to analyst estimates of $32.33 million. RxSight had a negative return on equity of 19.33% and a negative net margin of 31.92%. The business’s quarterly revenue was up 67.6% on a year-over-year basis. During the same period last year, the company posted ($0.40) EPS. Equities research analysts anticipate that RxSight, Inc. will post -0.81 EPS for the current year.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.